Similar to the finding of TBK1 as a potent target for HER2-positive breast cancer [65], an identification of molecular targets regulated by ERBB3 signal pathways will be beneficial to design a new regime for ERBB3-targeted therapy or a combination therapy for treating colorectal cancers. This evidence concerns the gene TBK1 and breast cancer.